KMTS

Business Context and Reporting Period

Kestra Medical Technologies, Ltd. (KMTS) is a commercial-stage medical device company focused on the Cardiac Recovery System platform, anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD). The company leases the device to patients at risk of sudden cardiac arrest, billing third-party payors including Medicare and private insurers. This Form 10-Q covers the quarterly period ended October 31, 2025, and the six months ended on that date. The company completed its Initial Public Offering (IPO) in March 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 53% year-over-year for both the three and six-month periods, driven by a 53-54% increase in the number of patients using the product while reimbursement rates remained consistent.
• Gross Profit Expansion: Gross profit increased 96% (Q/Q) and 102% (YTD) compared to the prior year. Gross margin improved due to a 20% decrease in cost of revenue per patient, attributed to better equipment utilization, volume efficiencies, and longer useful lives of components.
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses surged 79% for the quarter and 77% YTD. This increase was primarily due to personnel expenses (salaries, benefits, share-based compensation) to support commercial growth and costs associated with transitioning to a public company (legal, accounting, insurance).
• Net Loss: Net loss attributable to common shareholders increased 38% for the quarter and 28% YTD, reflecting the significant investment in commercial scaling and public company compliance costs.

Guidance, Outlook, and Risks

• Liquidity and Capital Resources: As of October 31, 2025, the company held $175.4 million in cash and cash equivalents. Management believes this, combined with revenue, is sufficient to fund operations for at least the next 12 months.
  • Subsequent Event: On December 4, 2025, the company completed a public offering of 6.9 million shares at $23.00 per share, raising net proceeds of approximately $149.2 million.
• Debt Obligations: The company has a Senior Secured Delayed Draw Term Loan with a principal balance of $45.0 million. An additional $15.0 million tranche is available through July 31, 2026, contingent on achieving a trailing twelve-month revenue run rate of $60.0 million.
• Internal Control Weaknesses: Management concluded that disclosure controls and procedures were not effective as of October 31, 2025, due to material weaknesses. These include insufficient resources in accounting/IT, lack of controls for complex transactions (e.g., lease classification, SG&A), and deficiencies in IT general controls (change management, user access). Remediation plans are underway.
• Risk Factors: Key risks include the ability to scale manufacturing, maintain regulatory approvals, secure reimbursement, and the potential need for additional funding if growth plans require more capital than currently available.

Investor Verification Checklist

• Remediation of Material Weaknesses: Verify the progress of hiring and implementing controls to address the identified internal control deficiencies, as these pose a risk to future financial reporting accuracy.
• Debt Covenant Compliance: Monitor the company's ability to achieve the $60.0 million trailing twelve-month revenue milestone required to access the remaining $15.0 million debt tranche.
• Reimbursement Trends: Confirm that reimbursement rates and payor coverage remain stable as the patient base expands, as this is the primary driver of revenue growth.
• Cash Burn Rate: Assess the sustainability of the current operating cash burn ($44.6 million over six months) against the newly raised capital from the December 2025 offering.
• Share-Based Compensation: Review the impact of significant share-based compensation expenses ($13.2 million YTD) on future dilution and operating margins.